Trials / Active Not Recruiting
Active Not RecruitingNCT03989414
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 424 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-92480 | Specified dose on specified days |
| DRUG | Bortezomib | Specified dose on specified days |
| DRUG | Dexamethasone | Specified dose on specified days |
| DRUG | Daratumumab | Specified dose on specified days |
| DRUG | Carfilzomib | Specified dose on specified days |
| DRUG | Elotuzumab | Specified dose on specified days |
| DRUG | Isatuximab | Specified dose on specified days |
| DRUG | Carfilzomib | Specified dose on specified days |
Timeline
- Start date
- 2019-09-30
- Primary completion
- 2026-11-30
- Completion
- 2026-11-30
- First posted
- 2019-06-18
- Last updated
- 2024-11-29
Locations
49 sites across 9 countries: United States, Canada, Czechia, Denmark, France, Germany, Greece, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03989414. Inclusion in this directory is not an endorsement.